Shares in US pharma giant Merck & Co (NYSE: MRK) jumped 4% on Monday, an unusual result for a big pharma, reflecting the level of excitement over its latest data release.
The firm has announced encouraging results for sotatercept, a novel activin signaling inhibitor picked up through its $11.5 billion acquisition of Acceleron Pharma.
Scientists believe the candidate has the potential to reach an area of significant unmet need in the pulmonary arterial hypertension (PAH) space, where there is no disease modifying therapy available for patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze